HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Online-Only Appendix All Versions of this Article: db08-0540v1 57/8/1999    most recent Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Google Scholar Articles by Dallaire, P. Articles by Marette, A. PubMed PubMed Citation Articles by Dallaire, P. Articles by Marette, A. Social Bookmarking                What's this?

Obese Mice Lacking Inducible Nitric Oxide Synthase Are Sensitized to the Metabolic Actions of Peroxisome Proliferator–Activated Receptor- Agonism

¹ Department of Anatomy and Physiology, Laval University, Québec, Québec, Canada
² Lipid Research Unit, Laval University Hospital Research Center, Québec, Québec, Canada
³ Laval Hospital Research Center, Québec, Québec, Canada
⁴ Molecular Nutrition Unit, Department of Nutrition and Biochemistry, University of Montreal and the Montreal Diabetes Research Centre, Centre Hospitalier de l'Université de Montréal, Montréal, Québec, Canada
⁵ Departments of Cell Biology and Medicine, Diabetes Research and Training Center, Albert Einstein College of Medicine, Bronx, New York
⁶ Touchstone Diabetes Center, Department of Internal Medicine, University of Texas Southwestern Medical Center, Dallas, Texas

Corresponding author: Dr. André Marette, andre.marette{at}crchul.ulaval.ca

OBJECTIVE—Synthetic ligands for peroxisome proliferator–activated receptor- (PPAR-) improve insulin sensitivity in obesity, but it is still unclear whether inflammatory signals modulate their metabolic actions. In this study, we tested whether targeted disruption of inducible nitric oxide (NO) synthase (iNOS), a key inflammatory mediator in obesity, modulates the metabolic effects of rosiglitazone in obese mice.

RESEARCH DESIGN AND METHODS—iNOS^–/– and iNOS^+/+ were subjected to a high-fat diet or standard diet for 18 weeks and were then treated with rosiglitazone for 2 weeks. Whole-body insulin sensitivity and glucose tolerance were determined and metabolic tissues harvested to assess activation of insulin and AMP-activated protein kinase (AMPK) signaling pathways and the levels of inflammatory mediators.

RESULTS—Rosiglitazone was found to similarly improve whole-body insulin sensitivity and insulin signaling to Akt/PKB in skeletal muscle of obese iNOS^–/– and obese iNOS^+/+ mice. However, rosiglitazone further improved glucose tolerance and liver insulin signaling only in obese mice lacking iNOS. This genotype-specific effect of rosiglitazone on glucose tolerance was linked to a markedly increased ability of the drug to raise plasma adiponectin levels. Accordingly, rosiglitazone increased AMPK activation in muscle and liver only in obese iNOS^–/– mice. PPAR- transcriptional activity was increased in adipose tissue of iNOS^–/– mice. Conversely, treatment of 3T3-L1 adipocytes with a NO donor blunted PPAR- activity.

CONCLUSIONS—Our results identify the iNOS/NO pathway as a critical modulator of PPAR- activation and circulating adiponectin levels and show that invalidation of this key inflammatory mediator improves the efficacy of PPAR- agonism in an animal model of obesity and insulin resistance.

CiteULike    Del.icio.us    Digg    Reddit    Technorati    What's this?